Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Core Insights - VolitionRx Limited has signed an agreement with a leading pharmaceutical company to utilize its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study, marking a significant milestone for the company [1][3] - The study is expected to generate substantial revenue for Volition over a 12-18 month period, with further projects under discussion [2] Company Developments - The Nu.Q® Discover program offers advanced assays for rapid epigenetic profiling, aiding drug developers and scientists from discovery to market readiness [1][9] - The collaboration allows Volition to leverage its nucleosome expertise to enhance clinical research, potentially improving patient selection for treatment [5][6] Market Positioning - This partnership highlights the growing recognition of Volition's nucleosome-based biomarkers in clinical development, aligning with the company's long-term goal of enabling precision therapy [4][7] - The application of Nu.Q® Discover in clinical trials positions Volition to expand its role in precision medicine and targeted therapeutic approaches [8]